- Home
- PMVP vs HOWL Comparison
PMVP vs HOWL Comparison
Compare PMVP & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | HOWL |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 64.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMVP | HOWL |
|---|---|---|
| Price | $1.25 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $6.50 |
| AVG Volume (30 Days) | 291.0K | ★ 796.4K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $0.56 |
| 52 Week High | $1.84 | $2.38 |
Technical Indicators
Market Signals| Indicator | PMVP | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 32.09 |
| Support Level | $1.11 | $0.56 |
| Resistance Level | $1.30 | $1.20 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 67.50 | 19.49 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.